Zealand Pharma shares surge 34% after successful trial of weight-loss drug

Today, February 26, the Danish pharmaceutical company Zealand Pharma announced about the good results of the second phase of a clinical trial of a drug for the treatment of liver diseases – survodutide. According to the company, 83% of patients taking the drug achieved “breakthrough results” in the treatment of certain liver diseases. Zealand Pharma is developing this drug together with the German pharmaceutical company Boehringer Ingelheim.

Following the announcement, Zealand Pharma shares rose 34%. This is due to the fact that survodutide is being developed not only as a drug for liver disease, but also as a drug for weight loss. Thus, the company is among quite numerous developers of such drugs, including Novo Nordisk, Eli Lilly, Novartis, etc. Over the past year, the popularity of such drugs grew updespite information about possible side effects their applications.

Yana Rozhdestvenskaya